Amgen Inc. AMGN

414.61 8.57 2.11% as of 25 Sep
Market cap
$219.1B
P/E
25.6×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Amgen Inc. (AMGN) Price to free cash flow

As of 25 September 2026, Amgen Inc. (AMGN) trades at a price to free cash flow of 23.0×. Over the past ten years it has ranged from 10.4× (September 2015) to 35.9× (September 2024); the current reading is higher than 90% of that period. That is above the Drug Manufacturers General industry median of 17.7× and above the Healthcare sector median of 19.5×.

Price to free cash flow, daily

Annual

Period Price to free cash flow Change
FY2025 23.0× 63.46%
FY2024 14.1× (38.84%)
FY2023 23.0× 36.30%
FY2022 16.9× 4.46%
FY2021 16.1× 13.24%
FY2020 14.2× (20.88%)
FY2019 18.0× 41.70%
FY2018 12.7× (0.99%)
FY2017 12.8× 4.55%
FY2016 12.3× (9.43%)

Quarterly

Period Price to free cash flow Change
Jun 2026 20.1× (13.75%)
Mar 2026 23.3× 1.33%
Dec 2025 23.0× 68.02%
Sep 2025 13.7× (7.43%)
42 more quarters

Against its own ten years

Low 10.4× High 35.9×
Ten-year median 15.0×
Current reading's percentile 90

Price to free cash flow against peers

Company Price to free cash flow
BMY Bristol Myers Squibb Company compare 11.2×
GILD Gilead Sciences, Inc. compare 14.5×
PFE Pfizer Inc. compare 16.0×
NVS Novartis AG compare 18.3×
NVO Novo Nordisk A/S compare 22.6×
MRK Merck & Co., Inc. compare 22.9×
AMGN Amgen Inc. 23.0×
ABBV AbbVie Inc. compare 25.7×
AZN AstraZeneca PLC compare 41.2×
Drug Manufacturers General industry median 17.7×
Healthcare sector median 19.5×
Market median 14.0×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on AMGN